ArticleCytotechnology2025
FTO curbs trophoblast cell biological behaviors through repressing ALDH1A1 expression.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- METTL3-Mediated m6A Modification of ACTR2 Promotes Trophoblast Cell Growth, Migration and Invasion in Unexplained Recurrent Spontaneous Abortion.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is one of the most common and serious documented gestational complications, and it is threatening the mother and the fetus, which is a notable burden on healthcare systems. Aldehyde dehydrogenase 1A1 (ALDH1A1), a cytosolic enzyme, shows vital physiological and pathophysiological functions in many areas. In the majority of cancer types, obesity-associated protein (FTO) is upregulated and exhibits an essential tumor-promoting role. We speculate that FTO and ALDH1A1 may play a significant role in the pathogenesis of PE by affecting the trophoblast cell biological behaviors. We analyzed differential expression genes (DEGs) in PE and non-PE groups in the GSE234726 dataset. The reverse-transcription quantitative polymerase chain reaction (qRT-PCR) and western blot assay were performed to test the mRNA and protein levels. The cell proliferation and apoptosis were examined using 5-Ethynyl-2'-deoxyuridine (EdU) and flow cytometry. The cell migration was investigated by wound healing assay and transwell assay. The ability of angiogenesis was tested by angiogenesis assay. The Spearman's rank correlation coefficient was used to analyze the correlation between ALDH1A1 expression and FTO expression. The m6A methylation site of ALDH1A1 mRNA was predicted using SRAMP website. The RNA immunoprecipitation (RIP) and m6A RNA immunoprecipitation (MeRIP) assay were performed to examine the binding relationship between ALDH1A1 and FTO. In PE, ALDH1A1 level is decreased. Silencing ALDH1A1 suppressed cell proliferation, migration, and angiogenesis and induced cell apoptosis. ALDH1A1 knockdown inhibited the expression of cyclin D1, anti-matrix metalloproteinase 9 (MMP9), and vascular endothelial growth factor (VEGF) and facilitated c-casp3 levels. The FTO expression was increased in PE placentas. Besides, the ALDH1A1 expression was negatively correlated with FTO levels, and FTO could target ALDH1A1. Mechanically, FTO repressed the biological behaviors of HTR-8/SVneo cells via ALDH1A1 down-regulation. FTO retards the HTR-8/SVneo cell biological function through knockdown of ALDH1A1. These results suggest that FTO and ALDH1A1 may play an important role in the pathogenesis of PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.